Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Aridis Pharmaceuticals Inc
ARDS
Healthcare
Biotechnology
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections...
, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ARDS)
New Post
View:
Posts & Comments
Threaded Posts
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 2:05am
Aridis Pharmaceuticals, Inc. (ARDS): A Promising Biotech Tac
https://beyondspx.com/2024/08/02/aridis-pharmaceuticals-inc-ards-a-promising-biotech-tackling-antibiotic-resistance/
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 18, 2023 10:33am
ARDS....saved all ur a$$es again ; )
N.L.O.D..... LoL
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Jul 18, 2023 8:57am
RE:ARDS....Do some research....NR after close....
Just what I thought....Lost all it's AH gains....no follow thru past the DTL....back to the "wood shed" for a good a$$ whoopin for this pig Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 17, 2023 7:42pm
ARDS....Do some research....NR after close....
AH runner with Volume and price action At $0.47 on 11mil shs.....at DTL....could be top ....maybe not ; ) No position Take a look tomorrow...Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on May 31, 2023 2:33pm
ARDS...42 support broke...now 37 just broke....
Has to hold and rally or next & last bastion of support is 30 cents I will say ....right now...this is done Save your money ; )
(72)
•••
Iseneschal
X
Post by
Iseneschal
on May 31, 2023 10:19am
ARDS ...early a.m runner on NR
1 st scalp of the day Cheers !
(11)
•••
Stockhunter101
X
Post by
Stockhunter101
on Jun 14, 2021 11:13am
$ARDS on WallStreetSignals Alert #ARDS
Aridis Pharmaceuticals products target #infectious #diseases that have a significant impact on life expectancy and address acute #medical needs Read more: https://t.co/6B18qluJey
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec